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In this issue ofCell Reports, Cullen et al. demonstrate that the release ofmature interleukin-1b relies
on necrotic plasmamembrane permeabilization. Thus, caspasesmay have evolved tomodulate the
inflammatory potential of cell death, not to execute it.Interleukin-1b (IL-1b) and IL-18 are crucial
to the inflammatory response, whether
this is elicited by microbial stimuli or
endogenous danger signals (Kroemer
et al., 2013). Secretion of biologically
active IL-1b and IL-18 proceeds via a
two-step mechanism. First, pro-IL-1b
and pro-IL-18 are synthesized upon the
Toll-like receptor 4 (TLR4)-driven transac-
tivation of IL1B and IL18 (‘‘signal I’’). Sec-
ond, a multiprotein complex commonly
known as the ‘‘NLRP3 inflammasome’’
catalyzes the proteolytic maturation of
IL-1b and IL-18, hence promoting their
release (‘‘signal II’’) (Latz et al., 2013).
Several stimuli, including ATP, ouabain
(a plasma membrane Na+/K+-ATPase
inhibitor), various immunological adju-
vants (e.g., L-leucyl-L-leucine methyl
ester [LLOMe]), and pore-forming toxins
(e.g., streptolysin O [SLO], nigericin, vali-
nomycin), activate the NLRP3 inflamma-
some. The release of biologically active
IL-1b and IL-18 in response to these
agents has been linked to K+ ion efflux
from the cytosol. Accordingly, the artificial
increase of extracellular K+ levels inhibits
IL-1b and IL-18 processing (Latz et al.,
2013). Until now, however, a unifiedmodel
explaining how mature IL-1b and IL-18
are secreted was missing. In this issue of
Cell Reports, Cullen et al. demonstrate
that the maturation and release of IL-1b
critically impinge on necrotic plasma
membrane permeabilization (PMP) (Cullen
et al., 2015).Cullen et al. test the simple hypothesis
that agents promoting IL-1b secretion do
so by triggering necrosis, which is asso-
ciated with rapid PMP (Galluzzi et al.,
2014a). Indeed, SLO, nigericin, valinomy-
cin, ATP, ouabain, and LLOMe all cause
PMP in THP-1 human monocytic cells,
correlating with the release of active
IL-1b upon priming with the TLR4 agonist
lipopolysaccharide (LPS). The PMP-
inducing activity of these molecules does
not depend on LPS priming and is not
blocked by pharmacological or genetic
inhibition of the NLRP3 inflammasome.
Conversely, the wide-spectrum caspase
inhibitor Z-VAD-fmk, as well as knock-
down of various NLRP3-inflammasome
components, efficiently blocks IL-1b
maturation and release from THP-1 cells
primedwith LPS and exposed to nigericin.
These findings indicate that the cytotox-
icity of SLO, nigericin, valinomycin, ATP,
ouabain, and LLOMe does not rely on the
activation of the NLRP3 inflammasome
(and hence on IL-1b signaling). IL-1b
release from some cell types, such
as bone-marrow-derived macrophages
(BMDMs), does not require signal II,mean-
ing that BMDMs produce IL-1b directly
upon LPS exposure. As hypothesized by
Cullen et al., LPS causes rapid PMP in
BDMCs, and thedegree of PMPcorrelates
with the amount of bioactive IL-1b de-
tected in culture supernatants. Thus,
when signal II is not required for IL-1b
secretion, signal I alone promotes PMP.Cell Reports 1The cytotoxic response of THP-1 cells
to agents associated with signal II does
not manifest morphological features of
apoptosis and is independent of caspase
3 (CASP3) and CASP7 activation. Accord-
ingly, CASP3 and CASP7 knockdown
fails to exert cytoprotective effects in
this setting. Similarly, neither necrosta-
tin-1 (a pharmacological inhibitor of
necroptosis) administration nor down-
regulation of various components of
the necroptotic machinery efficiently
prevents PMP induction by nigericin or
ouabain. On the basis of these observa-
tions, the authors conclude that signal II
is associated with ‘‘conventional necro-
sis.’’ However, the involvement of
other forms of regulated necrosis such
as mitochondrial permeability transition
(MPT)-driven necrosis or parthanatos,
which impinges on poly (ADP-ribose)
polymerase 1 (PARP1) signaling (Galluzzi
et al., 2014b), was not tested. The precise
mechanisms whereby SLO, nigericin,
valinomycin, ATP, ouabain, and LLOMe
trigger necrosis remain unknown.
Irrespective of this unresolved issue,
Cullen et al. demonstrate that the release
of IL-1b from cells exposed to agents
associated with signal II is non-specific;
i.e., it is accompanied by the release of
many other cytosolic proteins. Moreover,
the authors elegantly rule out the possi-
bilities that a subpopulation of necrosis-
resistant cells secretes IL-1b and that
pro-IL-1b is converted into biologically1, June 16, 2015 ª2015 The Authors 1501
Figure 1. Pro- and Anti-inflammatory Functions of Caspases
In the course of necrotic cell death, activation of the NLRP3 inflammasome
(which contains CASP1) exacerbates inflammation through proteolytic con-
version of pro-IL-1b into biologically active IL-1b. Conversely, CASP8 tonically
suppresses necroptosis, which is associated with the release of several
danger signals, limiting the inflammatory potential of cell death. Similarly, upon
activation by CASP9, CASP3 exerts anti-inflammatory functions by promoting
the exposure of phosphatidylserine (PS) on the surface of dying cells and by
inhibiting type I interferon (IFN) responses driven by MAVS. Thus, caspases
have a prominent impact on how the organism perceives regulated cell death.
Abbreviations are as follows: CFLAR, CASP8 and FADD-like apoptosis
regulator; ER, endoplasmic reticulum; FADD, Fas (TNFRSF6)-associated via
death domain; M, mitochondria; F, macrophage.active IL-1b extracellularly.
Finally, they show that known
inhibitors of IL-1b maturation
and release, including excess
extracellular K+ ions and
the antidiabetic drug glybur-
ide, actually inhibit necrotic
PMP. In summary, the obser-
vations by Cullen et al. sug-
gest that necrosis is neces-
sary and sufficient for the
secretion of bioactive IL-1b
as necrotic PMP allows for
the efflux of K+ ions required
for NLRP3 activation, as well
as for the unspecific release
of IL-1b.
The work by Cullen et al.
adds togrowingevidence sug-
gesting that caspases have
not evolved as executioners
of cell death (Galluzzi et al.,
2015), but as a means to
exacerbate (CASP1) or inhibit
(CASP8, CASP9, CASP3) its
inflammatory potential (Fig-
ure 1). Indeed, necroptosis(which has a robust inflammatory
outcome) is suppressed by a multiprotein
complex containing CASP8 (Pasparakis
and Vandenabeele, 2015). CASP9-medi-
ated CASP3 activation is required for
dying cells to expose phosphatidylserine
on the cell surface, resulting in rapid up-
take by phagocytes (Segawa et al.,
2014). Moreover, CASP3 actively inhibits
pro-inflammatory type I interferon
signaling elicited by MAVS in response to
cytosolic mtDNA (Rongvaux et al., 2014;1502 Cell Reports 11, June 16, 2015 ª2015 TWhite et al., 2014). It will be interesting to
investigate the fate of pro-IL-1b in LPS-
primed monocytes driven to CASP3- or
CASP8-dependent cell death, which is
associated with delayed PMP. It is
tempting to speculate (but remains to be
formally demonstrated) that these cells
will not release biologically active IL-1b,
perhaps as a direct consequence of
CASP9, CASP3, or CASP8 activation.
Further experiments are required to in-
crease our understanding of the relation-he Authorsship between intracellular
cell-death signaling and
organismal homeostasis.REFERENCES
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